SPRY2
SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.
Overview
Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2. Thereby acts as an antagonist of FGF-induced retinal lens fibre differentiation, may inhibit limb bud outgrowth and may negatively modulate respiratory organogenesis. Inhibits TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.
- 1 · What it is
SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.
- 2 · What goes wrong in cancer
Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2.
- 3 · How drugs use it
No product in this corpus aims at SPRY2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:11270 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O43597 (protein name, function text, keywords and locations (REST API)); CIViC gene SPRY2 (1 evidence items, 0 assertions, 1 variants; diseases: Gastric Adenocarcinoma (GraphQL API, CC0))
Biology
Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2. Thereby acts as an antagonist of FGF-induced retinal lens fibre differentiation, may inhibit limb bud outgrowth and may negatively modulate respiratory organogenesis. Inhibits TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells. Inhibits CBL/C-CBL-mediated EGFR ubiquitination. Location: Cytoplasm, cytoskeleton; Cell projection, ruffle membrane (UniProt). Locus 13q31.1 (HGNC).
- Gastric & gastro-oesophageal junction cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SPRY2" OR ABSTRACT:"SPRY2" OR TITLE:"sprouty RTK signaling antagonist 2" OR ABSTRACT:"sprouty RTK signaling antagonist 2" OR TITLE:"Protein sprouty homolog 2" OR ABSTRACT:"Protein sprouty homolog 2" OR TITLE:"hSPRY2" OR ABSTRACT:"hSPRY2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SPRY2, not a curated reading list.